ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "osteoarthritis and pain"

  • Abstract Number: 1364 • 2018 ACR/ARHP Annual Meeting

    Treatment of Knee Osteoarthritis with SM04690 Improved WOMAC A1 “Pain on Walking” – Results from a 52-Week, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of a Novel, Intra-Articular, Wnt Pathway Inhibitor

    Jeyanesh Tambiah1, Sarah Kennedy1, Heli Ghandehari1, Christopher Swearingen1 and Marc C. Hochberg2, 1Samumed, LLC, San Diego, CA, 2University of Maryland School of Medicine, Baltimore, MD

    Background/Purpose: Knee osteoarthritis (OA) is characterized by pain, functional limitation, and physical disability due to articular cartilage degradation and bone remodeling. Wnt signaling is involved…
  • Abstract Number: 1377 • 2018 ACR/ARHP Annual Meeting

    Knee Osteoarthritis Symptom Duration Is Associated with Conditioned Pain Modulation and Vibration Perception Threshold Impairment

    Kharma C. Foucher1, Samuel Chmell2 and Carol Courtney3, 1Kinesiology and Nutrition, University of Illinois at Chicago, Chicago, IL, 2Orthopedic Surgery, University of Illinois at Chicago, Chicago, IL, 3Physical Therapy, University of Illinois at Chicago, Chicago, IL

    Background/Purpose: Impaired descending pain inhibition has been observed in people with knee OA and may be associated with development of chronic pain as well as…
  • Abstract Number: 425 • 2018 ACR/ARHP Annual Meeting

    Efficacy, Safety, and Tolerability of ONO-4474, an Orally Available Pan-Tropomyosin Receptor Kinase Inhibitor, in Japanese Patients with Moderate-to-Severe Osteoarthritis of the Knee: A Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Comparative Study

    Naoki Ishiguro1, Shusuke Oyama2, Ryunosuke Higashi3 and Kunio Yanagida4, 1Orthopaedic Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan, 2Data Science, Ono Pharmaceutical Co., Ltd., Osaka, Japan, 3Translational Science, Translational Medicine Center, Ono Pharmaceutical Co., Ltd., Osaka, Japan, 4Translational Science, Translational Medicine Center, Ono Pharmaceutical Co., Ltd, Osaka, Japan

    Background/Purpose: ONO-4474 is an orally available, peripheral-specific, pan-tropomyosin receptor kinase (pan-Trk) inhibitor currently under development for treatment of musculoskeletal pain in OA patients. This study…
  • Abstract Number: 1920 • 2018 ACR/ARHP Annual Meeting

    Is There Objective Evidence of Neuropathy in Knee Osteoarthritis Based on Clinical Evaluation?

    Priyanka Ballal1, Joachim Scholz2, Laura Frey-Law3, Na Wang1, Michael C. Nevitt4, Cora E. Lewis5 and Tuhina Neogi6, 1Boston University School of Medicine, Boston, MA, 2Departments of Anesthesiology and Pharmacology, Columbia University Medical Center, New York, NY, 3University of Iowa, Iowa City, IA, 4Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA, 5University of Alabama Birmingham, Birmingham, AL, 6Clinical Epidemiology Research and Training Unit, Boston University School of Medicine, Boston, MA

    Background/Purpose: Self-reported descriptors of pain in knee osteoarthritis (OA) such as burning and stabbing pain are suggestive of a neuropathic component of pain beyond that…
  • Abstract Number: 426 • 2018 ACR/ARHP Annual Meeting

    The Association of Dietary Patterns with Knee Symptoms and MRI Detected Structures in Patients with Knee Osteoarthritis (OA)

    Shuang Zheng1, Feitong Wu1, Flavia Cicuttini2, Anita E Wluka2, Dawn Aitken1, Tania Winzeberg1,3, Leigh Blizzard1, Graeme Jones4 and Changhai Ding1,5, 1Menzies Institute for Medical Research, University of Tasmania, Hobart, Australia, 2Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Australia, 3Faculty of Health, University of Tasmania, Hobart, Australia, 4Menzies Institute for Medical Research, Menzies Institute for Medical Research, University of Tasmania, Hobart, Australia, 5Clinical Research Centre, Zhujiang Hospital, Southern Medical University, Guangzhou, China

    The association of dietary patterns with knee symptoms and MRI detected structures in patients with knee osteoarthritis (OA)Abstract Background/Purpose: This study aimed to examine the…
  • Abstract Number: 1994 • 2018 ACR/ARHP Annual Meeting

    Osteoarthritis Severity Is Reduced By Intra-Articular Administration of Hydrogen Sulfide

    Elena F. Burguera1,2, Angela Vela-Anero3, Carlos Vaamonde-Garcia3, Tamara Hermida-Gómez1,2, Purificacion Filgueira-Fernandez1,2, Lucía Gato-Calvo2, Rosa Meijide-Failde4 and Francisco J Blanco5, 1CIBER-BBN, Madrid, Spain, 2Unidad de Medicina Regenerativa, Grupo de Investigación en Reumatología, Agrupación Estratégica CICA-INIBIC, Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas, Universidade de A Coruña (UDC), A Coruña, Spain, 3Department of Physiotherapy, Medicine and Biological sciences, Tissue Engineering and Regenerative Medicine group (University of A Coruña), A Coruña, Spain, 4Department of Physiotherapy, Medicine and Biological Sciences, Tissue Engineering and Regenerative Medicine group (University of A Coruña), A Coruña, Spain, 5Grupo de Investigación en Reumatología, Instituto de Investigación Biomédica de A Coruña (INIBIC), Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas. Universidade da Coruña (UDC), A Coruña, Spain

    Background/Purpose: Hydrogen sulphide (H2S) is recognized as a therapeutic target in osteoarthritis (OA). Exogenous supplementation with synthetic salts in in vitro models of OA has…
  • Abstract Number: 62 • 2017 ACR/ARHP Annual Meeting

    Convergence of Joint Repair and Pain Pathways Via Nerve Growth Factor and p75 Expressing Mesenchymal Stem Cells in Established Osteoarthritis

    Thomas Baboolal1, Sumaiya Al Hinai2, Elena Jones2, Jill Reckless3, Martyn Foster4, Rachel Doyle5, Kerry af Forselles4, Simon Westbrook4 and Dennis McGonagle2, 1PhD, Leeds, United Kingdom, 2Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, 3Rxcelerate Ltd, Cambridge, United Kingdom, 4Levicept Ltd, Ramsgate, United Kingdom, 5Tetrad Discovery Ltd, Ramsgate, United Kingdom

    Background/Purpose: Nerve growth factor (NGF) is a key regulator of pain and anti-NGF therapy reduces osteoarthritis (OA) associated pain. However, anti-NGF therapy is associated with…
  • Abstract Number: 1193 • 2017 ACR/ARHP Annual Meeting

    A Randomized, Placebo-Controlled, Double-Blind, Phase II Clinical Trial of the First-in-Class Imidazoline-2 Receptor Ligand CR4056 in Pain from Knee Osteoarthritis and Disease Phenotypes

    Lucio C. Rovati1, Nadia Brambilla1, Tomasz Blicharski2, Nicholas J Probert3, Cristina Vitalini1, Giampaolo Giacovelli1, Federica Girolami1 and Massimo D'Amato1, 1Clinical Research Department, Rottapharm Biotech, Monza, Italy, 2Lubelskie Centrum Diagnostyczne, Świdnik, Poland, 3MAC Clinical Research, Manchester, United Kingdom

    Background/Purpose: CR4056 is a novel imidazoline-2 receptor (I2R) ligand endowed with potent analgesic activities in several and diverse animal models of nociceptive and neuropathic pain,…
  • Abstract Number: 1195 • 2017 ACR/ARHP Annual Meeting

    Efficacy and Safety of Subcutaneous Tanezumab in Patients with Knee or Hip Osteoarthritis (NCT01089725)

    Charles A. Birbara1, Eugene J. Dabezies2, Aimee M. Burr3, Robert J. Fountaine4, Michael D. Smith3, Mark T. Brown3, Christine R. West3, Rosalinda H. Arends3 and Kenneth M. Verburg3, 1University of Massachusetts Medical School, Worcester, MA, 2Pensacola Research Consultants, Pensacola, FL, 3Pfizer, Inc., Groton, CT, 4Pfizer, Inc., Grotoon, CT

    Background/Purpose : Tanezumab (TNZ) is a monoclonal antibody that inhibits nerve growth factor and reduces hip or knee osteoarthritis (OA) pain. A placebo-controlled phase 3…
  • Abstract Number: 2183 • 2017 ACR/ARHP Annual Meeting

    Two-Year Changes in Knee Osteoarthritis Symptoms: Comparing Clinical Relevance of Patient-Reported Outcomes By Anchoring to Knee Replacement

    C. Kent Kwoh1, Hans Guehring2, Erin Ashbeck3, Michael J Hannon4 and Aida Aydemir5, 1University of Arizona Arthritis Center, Tuscan, AZ, 2Merck KGaA, Darmstadt, Germany, 3The University of Arizona Arthritis Center, Tucson, AZ, 4Medicine, University of Pittsburgh, Pittsburgh, PA, 5EMD Serono Research & Development Institute, Inc. (a business of Merck KGaA, Darmstadt, Germany), Billerica, MA

    Background/Purpose: Randomized controlled trials (RCTs) of interventions for knee OA (KOA) may include a patient-reported outcome (PRO) measure as a primary endpoint. Several measures of…
  • Abstract Number: 2186 • 2017 ACR/ARHP Annual Meeting

    The Role of Hip Injury in Pain Exacerbation in Hip Osteoarthritis: an Internet-Based Case-Crossover Study

    Kai Fu1, Joanna Makovey2, Ben Metcalf3, Kim Bennell3, Yuqing Zhang4, Rebecca Asher5, Sarah Meneses2, Leticia Deveza2 and David Hunter2, 1Rheumatology, Institute of Bone and Joint Research, Kolling Institute, University of Sydney, Syndey, Australia, 2Rheumatology, Institute of Bone and Joint Research, Kolling Institute, University of Sydney, Sydney, Australia, 3Centre for Health, Exercise and Sports Medicine, Department of Physiotherapy, University of Melbourne, Melbourne, Australia, 4School Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, 5NHMRC Clinical Trials Centre, University of Sydney, Sydney, Australia

    Background/Purpose: Pain is the main symptom in hip osteoarthritis (OA) and many patients experience recurrent pain exacerbations. The purpose of this study is to evaluate…
  • Abstract Number: 2204 • 2017 ACR/ARHP Annual Meeting

    Neuropathic Pain in Patients with Knee Osteoarthritis and Related Factors: A Multicenter Longitudinal Study-Preliminary Report

    Ece Kaptanoglu1, Ozlem Şahin2, Tiraje Tuncer3, Sami Hizmetli1, Lale Altan4, Figen Ayhan5, Ajda Bal6, Meral Bilgilisoy7, Gulnur Bozbas8, Lale Cerrahoglu9, Remzi Cevik10, Tuncay Duruoz11, Deniz Dulgeroglu6, Gulcan Gurer12, Savas Gursoy13, Simin Hepguler14, Cahit Kacar15, Taciser Kaya16, Meltem Melikoglu17, Kemal Nas18, Suheda Ozcakir19, Senay Ozdolap20, merih Saridogan21, Selda Sarikaya20, Dilsad Sindel22, Omer F Şendur8, Canan Tikiz23 and Hatice Ugurlu24, 1Department of Physical Medicine and Rehabilitation, Division of Rheumatology, Cumhuriyet University School of Medicine, Sivas, Turkey, 2Department of Physical Medicine and Rehabilitation, Cumhuriyet University School of Medicine, Sivas, Turkey, 3Department of Physical Medicine and Rehabilitation, Akdeniz University School of Medicine, Antalya, Turkey, 4Department of Physical Medicine and Rehabilitation, Division of Rheumatology, Uludag University School of Medicine, Bursa, Turkey, 5Department of Physical Medicine and Rehabilitation, University of Health Ankara Training and Research Hospital, Ankara, Turkey, 6Department of Physical Medicine and Rehabilitation, University of Health Sciences Diskapi Yildirim Beyazit Training and Research Hospital, Ankara, Turkey, 7Department of Physical Medicine and Rehabilitation, University of Health Sciences Antalya Training and Research Hospital, Antalya, Turkey, 8Department of Physical Medicine and Rehabilitation, Adnan Menderes University School of Medicine, Aydin, Turkey, 9Department of Physical Medicine and Rehabilitation, Celal Bayar University School of Medicine, Manisa, Turkey, 10Department of Physical Medicine and Rehabilitation, Dicle University School of Medicine, Diyarbakir, Turkey, 11Department of Physical Medicine and Rehabilitation, Division of Rheumatology, Marmara University School of Medicine, Istanbul, Turkey, 12Department of Physical Medicine and Rehabilitation, Division of Rheumatology, Adnan Menderes University School of Medicine, Aydin, Turkey, 13Department of Physical Medicine and Rehabilitation, Gaziantep University School of Medicine, Gaziantep, Turkey, 14Department of Physical Medicine and Rehabilitation, Ege University School of Medicine, Izmir, Turkey, 15Department of Physical Medicine and Rehabilitation, Division of Rheumatology, Akdeniz University School of Medicine, Antalya, Turkey, 16Department of Physical Medicine and Rehabilitation, University of Health Sciences İzmir Bozyaka Training and Research Hospital, Izmir, Turkey, 17Department of Physical Medicine and Rehabilitation, Division of Rheumatology, Ataturk University School of Medicine, Erzurum, Turkey, 18Department of Physical Medicine and Rehabilitation, Sakarya University School of Medicine, Sakarya, Turkey, 19Department of Physical Medicine and Rehabilitation, Uludag University School of Medicine, Bursa, Turkey, 20Department of Physical Medicine and Rehabilitation, Bulent Ecevit University School of Medicine, Zonguldak, Turkey, 21Department of Physical Medicine and Rehabilitation, Istanbul University Cerrahpasa School of Medicine, Istanbul, Turkey, 22Department of Physical Medicine and Rehabilitation, Istanbul University Istanbul Faculty of Medicine, Istanbul, Turkey, 23Celal Bayar University School of Medicine, Manisa, Turkey, 24Department of Physical Medicine and Rehabilitation, Necmettin Erbakan University Meram School of Medicine, Konya, Turkey

    Background/Purpose: Neuropathic pain (NP) was accused for increased pain and reduced functional capacity in knee osteoarthritis (KO). Here we aimed to find out the prevalence…
  • Abstract Number: 2232 • 2017 ACR/ARHP Annual Meeting

    A Role for CCR2 in Chronic Behavioral and Neuroimmune Changes in the DMM Model of Osteoarthritis

    Phuong Tran1, Shingo Ishihara2, Rachel E. Miller3, Richard J. Miller4 and Anne-Marie Malfait1, 1Rheumatology, Rush University Medical Center, Chicago, IL, 2Internal Medicine, Rush University Medical Center, Chicago, IL, 3Biochemistry, Rush University Medical Center, Chicago, IL, 4Pharmacology/Medical Humanities and Bioethics, Northwestern University, Chicago, IL

    Background/Purpose: The aim of this study was to explore pain-related behaviors and associated cellular changes in the pain pathway in experimental osteoarthritis (OA) induced by…
  • Abstract Number: 2236 • 2017 ACR/ARHP Annual Meeting

    Neuropathic Pain in End-Stage Hip and Knee Osteoarthritis: Differences between Men and Women and Differential Associations with Pain at Rest and Pain on Activity

    J. Denise Power1, Anthony V. Perruccio1, Rajiv Gandhi1, Christian Veillette1, J. Roderick Davey1, Khalid Syed1, Nizar Mahomed1 and Y. Raja Rampersaud2, 1Arthritis Program, Krembil Research Institute, University Health Network, Toronto, ON, Canada, 2Arthritis Program, Krembil Research Institute, University Health Network, Torotno, ON, Canada

    Background/Purpose: There is increasing support in the literature for a neuropathic component to OA pain. Our primary objective was to determine whether pain at rest…
  • Abstract Number: 2852 • 2017 ACR/ARHP Annual Meeting

    Widespread Pain Prior to Total Knee Replacement (TKR) Is Associated with Increased Risk of No Clinical Improvement in Pain Among Women

    Ernest Vina1, Di Ran2, Erin L. Ashbeck2 and C. Kent Kwoh3, 1Rheumatology, University of Arizona, Tucson, AZ, 2The University of Arizona Arthritis Center, Tucson, AZ, 3University of Arizona, Tucson, AZ

    Background/Purpose: Up to 47% of individuals may not have clinically significant improvement following joint replacement surgery. Evidence also suggests that women are less likely to…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • …
  • 7
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology